[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ciprofloxacin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ciprofloxacin":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100548887",false,"NCT06426836","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation","PADECMO","Inclusion Criteria:\n\n* patients admitted to the pediatric intensive care unit or cardiac intensive care unit\n* patient age : 1,8 kg-15 years\n* patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)\n* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)\n* extracorporeal membrane oxygenation circuit\n\nExclusion Criteria:\n\n* no catheter in place for blood sampling\n* absence of parental\u002Fpatient consent\n* known hypersensitivity to beta-lactam antibiotics and ciprofloxacin","ALL","15 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).",[26,27,28,29,30,31,32,33,34],"Pharmacokinetics","Amoxicillin-clavulanate","Piperacillin-tazobactam","Meropenem","Cefazolin","Teicoplanin","Vancomycin","Ciprofloxacin","Amikacin","RECRUITING","2026-01-15",{"date":38,"type":39},"2026-01-16","ACTUAL",{"date":41,"type":39},"2016-08-19",{"date":43,"type":20},"2026-07-01",{"name":45,"class":46},"University Hospital, Ghent","OTHER",3,{"id":49,"slug":4,"hasResults":10,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":10,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100244176","NCT02456974","Antibiotic Dosing in Pediatric Intensive Care","ADIC","Inclusion Criteria:\n\n* patients admitted to the pediatric intensive care unit\n* patient age\u002Fweight : 1,8 kg-15 years\n* patient receiving antibiotic treatment (piperacillin-tazobactam, amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, amikacin) via intermittent infusion regimen or continuous infusion according to institutional treatment guidelines\n* intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)\n\nExclusion Criteria:\n\n* no catheter in place for blood sampling\n* absence of parental\u002Fpatient consent\n* known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones, aminoglycosides\n* extracorporeal circuit (haemodialysis, ECMO, peritoneal dialysis )","1 Day","16 Years",{"count":57,"type":20},640,"3 Days","OBSERVATIONAL","Pharmacokinetics of antibiotics in critically ill neonates, infants and children",[26,27,28,32,31,29,33,34],{"date":38,"type":39},{"date":64,"type":4},"2012-05",{"date":66,"type":20},"2027-09-01",{"name":45,"class":46},1,""]